A.Menarini Diagnostics Announces Agreement with Skyla Corporation in the area of Point of Care Testing

Hsinchu, Taiwan and Florence, Italy, July 24th, 2020

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR^® POC instrument.

On August 20th the German Minister of Health, Jens Spahn visited the Red Cross Hospital of Mölln-Ratzeburg.

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

Menarini Diagnostics acquires EOS Preanalytics and Point Of Care company assets

FLORENCE, January 15th, 2021 - Menarini Diagnostics, a company of the Menarini Group

1 2 3 4 5 6 7

Våra värderingar

Fyra värdegrunder som gett liv till Menarini och formgett dess historia

LÄS MER »

A. Menarini Diagnostics S.r.l., Italien Filial (Sverige) | Single member company | Registered office: Via Sette Santi 3 - 50131 Florence (Italy) | Registration no. in registrar of companies: 05478500480 | Registrar of companies' office: Florence | Registered capital: € 100,000 fully paid-in | Capital reported in last financial statement: € 100,000

A.Menarini Diagnostics Announces Agreement with Skyla Corporation in the area of Point of Care Testing

Hsinchu, Taiwan and Florence, Italy, July 24th, 2020

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR® POC instrument.

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

Menarini Diagnostics acquires EOS Preanalytics and Point Of Care company assets

FLORENCE, January 15th, 2021 - Menarini Diagnostics, a company of the Menarini Group

Våra värderingar

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR^® POC instrument.

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.